Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Korsuva difelikefalin Chronic kidney disease Do not reimburse Complete
Koselugo selumetinib Neurofibromatosis type 1 Reimburse with clinical criteria and/or conditions Complete
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Do not list Complete
Kuvan Sapropterin dihydrochloride Phenylketonuria N/A Complete
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Reimburse with clinical criteria and/or conditions Complete
Kymriah tisagenlecleucel Relapsed or refractory follicular lymphoma Reimburse with clinical criteria and/or conditions Complete
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn
Kynmobi apomorphine hydrochloride Parkinson’s disease Reimburse with clinical criteria and/or conditions Complete
Kyprolis Carfilzomib Multiple Myeloma (relapsed) Reimburse with clinical criteria and/or conditions Complete
Kyprolis (with lenalidomide) Carfilzomib (with lenalidomide) Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete